Stockreport

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF 24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant i [Read more]